GPD2
Basic information
Region (hg38): 2:156435290-156613735
Links
Phenotypes
GenCC
Source: 
- diabetes mellitus, noninsulin-dependent (No Known Disease Relationship), mode of inheritance: AD
ClinVar
This is a list of variants' phenotypes submitted to 
- not_specified (78 variants)
- not_provided (9 variants)
- GPD2-related_disorder (7 variants)
- Type_2_diabetes_mellitus (3 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the GPD2 gene is commonly pathogenic or not. These statistics are base on transcript: NM_000000408.5. Only rare variants are included in the table.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUSVUS | Likely benignLB | BenignB | Sum | 
|---|---|---|---|---|---|---|
| synonymous | 6 | |||||
| missense | 78 | 84 | ||||
| nonsense | 0 | |||||
| start loss | 0 | |||||
| frameshift | 0 | |||||
| splice donor/acceptor (+/-2bp) | 0 | |||||
| Total | 1 | 0 | 78 | 10 | 1 | 
GnomAD
Source: 
| Gene | Type | Bio Type | Transcript | Coding Exons | Length | 
|---|---|---|---|---|---|
| GPD2 | protein_coding | protein_coding | ENST00000310454 | 16 | 178446 | 
| pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p | 
|---|---|---|---|---|---|---|
| 8.13e-11 | 0.970 | 125488 | 0 | 260 | 125748 | 0.00103 | 
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
|---|---|---|---|---|---|---|
| Missense | 0.724 | 361 | 402 | 0.898 | 0.0000219 | 4748 | 
| Missense in Polyphen | 141 | 166.97 | 0.84444 | 1884 | ||
| Synonymous | -0.714 | 150 | 139 | 1.08 | 0.00000736 | 1426 | 
| Loss of Function | 2.23 | 22 | 36.5 | 0.602 | 0.00000180 | 454 | 
LoF frequencies by population
| Ethnicity | Sum of pLOFs | p | 
|---|---|---|
| African & African-American | 0.00150 | 0.00150 | 
| Ashkenazi Jewish | 0.000497 | 0.000496 | 
| East Asian | 0.000490 | 0.000489 | 
| Finnish | 0.000324 | 0.000323 | 
| European (Non-Finnish) | 0.00161 | 0.00160 | 
| Middle Eastern | 0.000490 | 0.000489 | 
| South Asian | 0.000523 | 0.000523 | 
| Other | 0.000980 | 0.000978 | 
dbNSFP
Source: 
- Pathway
- Glycerophospholipid metabolism - Homo sapiens (human);Mitochondrial Electron Transport Chain;Familial lipoprotein lipase deficiency;Glycerol Phosphate Shuttle;Glycerolipid Metabolism;Glycerol Kinase Deficiency;Phospholipid Biosynthesis;D-glyceric acidura;Fatty Acid Beta Oxidation;miR-targeted genes in lymphocytes - TarBase;miR-targeted genes in muscle cell - TarBase;Metabolism of lipids;Metabolism;glycerol-3-phosphate shuttle;Glycerophospholipid metabolism;Triglyceride catabolism;Triglyceride metabolism;Glycerophospholipid biosynthesis;Phospholipid metabolism;Synthesis of PA;glycerol degradation (Consensus) 
Recessive Scores
- pRec
- 0.514
Intolerance Scores
- loftool
- 0.356
- rvis_EVS
- 0.22
- rvis_percentile_EVS
- 68.49
Haploinsufficiency Scores
- pHI
- 0.436
- hipred
- Y
- hipred_score
- 0.591
- ghis
- 0.529
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.847
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium | 
| Primary Immunodeficiency | Medium | Medium | Medium | 
| Cancer | Medium | Medium | Medium | 
Mouse Genome Informatics
- Gene name
- Gpd2
- Phenotype
- vision/eye phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); reproductive system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); liver/biliary system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); homeostasis/metabolism phenotype; endocrine/exocrine gland phenotype; adipose tissue phenotype (the observable morphological and physiological characteristics of mammalian fat tissue that are manifested through development and lifespan); growth/size/body region phenotype;
Gene ontology
- Biological process
- gluconeogenesis;glycerophosphate shuttle;glycerol catabolic process;multicellular organism growth;camera-type eye development;glycerol-3-phosphate catabolic process
- Cellular component
- mitochondrion;mitochondrial inner membrane;glycerol-3-phosphate dehydrogenase complex
- Molecular function
- glycerol-3-phosphate dehydrogenase [NAD+] activity;glycerol-3-phosphate dehydrogenase (quinone) activity;calcium ion binding;sn-glycerol-3-phosphate:ubiquinone-8 oxidoreductase activity